Os melanomas malignos em cães são uma das mais frequentes neoplasias diagnosticadas na cavidade oral. Infiltração local, recidiva (15-41%) e o alto potencial para metástases em linfonodos regionais (18-53%) e pulmões (23-27%) nos animais acometidos, conferem uma menor sobrevida (131-818 dias), ressaltando a necessidade e importância do estudo de novas terapias para o tratamento efetivo da doença. As uroquinases (UPA) e metaloproteinases (MMPs) são proteases superexpressas em uma variedade de células tumorais e raramente estão presentes em células fisiologicamente normais. A toxina do Bacillus anthracis é composta por três proteínas chamadas: fator letal (LF), fator de edema (EF) e antígeno protetor (PA). A toxina foi reengenheirada para a formação de dois tipos de PAs chamadas PAU2-R200A e PAL1-I207R, ativadas por UPA e MMPs da superficie das células tumorais, respectivamente, formando um complexo semelhante a um poro celular para permitir a internalização da LF. A citotoxicidade dessa associação reengenheirada PAU2-R200A, PAL1-I207R e LF ocorre quando a LF atinge o meio intracelular e causa a morte celular por interrupção da via de sinalização celular MAPkinase. O objetivo deste estudo é avaliar o potencial terapêutico da toxina reengenheirada do Bacillus anthracis, PAU2-R200A, PAL1-I207R e LF, dependentes de UPA e MMP, em melanomas orais de cães. Três etapas foram propostas para este estudo: o estudo in vitro da citotoxicidade de 5 linhagens de melanomas caninos submetidas à toxina reengenheirada, a avaliação da expressão de UPA e MMP em amostras parafinadas de melanoma oral canino e o tratamento intratumoral com a toxina modificada em cães com melanomas orais espontâneos. A linhagem GMGD2 foi a única que demonstrou sensibilidade à toxina estudada, apesar da concentração inibitória de 50% das células ter sido alta (IC50=4.964,16 mg/dl) em relação a linhagem controle HT29-RJ (IC50=179,47). As demais linhagens não demostraram redução da viabilidade celular com o aumento da concentração da toxina reengenheirada e não atingiram a IC50. Dentre as amostras de melanomas submetidos a imuno-histoquimica, 76,6% expressavam tanto uroquinases quanto metaloproteinases. Melanomas orais espontâneos de cães variando de 231,8 a 18601,6 mm3 em volume, sem evidências de metástases, foram tratados com as aplicações da toxina modificada por via intratumoral, previamente à excisão, realizada nos dias 07 ou 14 do tratamento. Dentre os animais estudados, todos apresentaram evolução favorável classificada como doença estável e resposta parcial. Somente um animal apresentou reação local. Nenhum dos pacientes apresentou efeito colateral sistêmico importante. Os resultados sugerem que existe potencial terapêutico da toxina reengenheirada do Bacillus anthracis sobre os melanomas bucais caninos e futuros ensaios clínicos são possíveis em cães e de extrema importância para o estudo mais aprofundado da toxina como nova terapia antineoplásica / Malignant melanomas in dogs are one of the most frequent malignancies diagnosed in the oral cavity. Local infiltration, recurrence (15-41%) and the high potential for regional lymph nodes metastases (18-53%) and lungs (23-27%) in the affected animals, confer a lower survival (131-818 days), emphasizing the necessity and importance of the study of new therapies for the effective treatment of the disease. Urokinase (UPA) and metalloproteinases (MMPs) are overexpressed proteases in a variety of tumor cells and are rarely present in normal physiological cells. Bacillus anthracis toxin is composed of three proteins called lethal factor (LF), edema factor (EF) and protective antigen (PA). The toxin was re-engineered for the formation of two types of PAs called PAU2-R200A and PAL1-I207R, activated by UPA and MMPs from the surface of tumor cells, respectively, forming a cell-like complex to allow the internalization of the LF. The cytotoxicity of this association PAU2-R200A, PAL1-I207R and LF occurs when LF reaches the intracellular environment and causes cell death by disruption of the MAPkinase cell signaling pathway. The objective of this study is to evaluate the therapeutic potential of UPA and MMP-dependent Bacillus anthracis toxin (PAU2- R200A, PAL1-I207R and LF) to treat oral melanomas in dogs. Three steps were proposed: cytotoxicity assay of 5 lineages of canine melanomas submitted to the reengineered toxin, immunohistochemistry study for UPA and MMP expression in paraffin samples of canine oral melanoma and intratumoral treatment with toxin in dogs with spontaneous oral melanomas. The lineage GMGD2 was the only one that showed sensitivity to the toxin studied, although 50% inhibitory concentration of the cells was high (IC50 = 4,964.16 mg / dl) in relation to the HT29-RJ control lineage (IC 50 = 179.47). Among the samples of melanomas submitted to immunohistochemistry, 76.6% expressed both urokinase and metalloproteinases. Spontaneous oral melanomas of dogs ranging volume from 231.8 to 18601.6 mm3 with no evidence of distant metastases, were treated with the applications of intratumoral re-engineered toxin prior to surgical excision. All of them has presented favorable evolution classified as stable disease and partial response. Only one animal had a local allergic reaction. None of the patients had a significant systemic side effects. The results suggest that there is a potential therapeutic effect of re-engineered anthrax toxin on canine melanomas and future clinical trials are possible in dogs and extremely important for further studies on the role of the B. anthracis toxin as a new antineoplastic agent

Diss. (sammanfattning) Uppsala : Sveriges lantbruksuniversitet, 2006. / Härtill 5 uppsatser.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2009. / Title from first page of PDF file (viewed on June 10, 2009). Includes bibliographical references.

Thesis (M.S.)--Brigham Young University. Dept. of Microbiology and Molecular Biology, 2007. / Includes bibliographical references (p. 29-31).

Philosophiae Doctor - PhD / Supervised machine learning approaches have been applied successfully to the prediction of protein-protein interactions (PPIs) within a single organism, i.e., intra-species predictions. However, because of the absence of large amounts of experimentally validated PPIs data for training and testing, fewer studies have successfully applied these techniques to host-pathogen PPI, i.e., inter-species comparisons. Among the host-pathogen studies, most of them have focused on human-virus interactions and specifically human-HIV PPI data. Additional improvements to machine learning techniques and feature sets are important to improve the classification accuracy for host-pathogen protein-protein interactions prediction. The primary aim of this bioinformatics thesis was to develop a binary classifier with an appropriate feature set for host-pathogen protein-protein interaction prediction using published human-Hepatitis C virus PPI, and to test the model on available host-pathogen data for human-Bacillus anthracis PPI. Twelve different feature sets were compared to find the optimal set. The feature selection process reveals that our novel quadruple feature (a subsequence of four consecutive amino acid) combined with sequence similarity and human interactome network properties (such as degree, cluster coefficient, and betweenness centrality) were the best set. The optimal feature set outperformed those in the relevant published material, giving 95.9% sensitivity, 91.6% specificity and 89.0% accuracy. Using our optimal features set, we developed a neural network model to predict PPI between human-Mycobacterium tuberculosis. The strategy is to develop a model trained with intra-species PPI data and extend it to inter-species prediction. However, the lack of experimentally validated PPI data between human-Mycobacterium tuberculosis (Mtuberculosis), leads us to first assess the feasibility of using validated intra-species PPI data to build a model for inter-species PPI. In this model we used human intra-species PPI combined with Bacillus anthracis intra-species data to develop a binary classification model and extend the model for human-Bacillus anthracis inter-species prediction. Thus, we test our hypotheses on known human-Bacillus anthracis PPI data and the result shows good performance with 89.0% as average accuracy. The same approach was extended to the prediction of PPI between human-Mycobacterium tuberculosis. The predicted human-M-tuberculosis PPI data were further validated using functional enrichment of experimentally verified secretory proteins in M-tuberculosis, cellular compartment analysis and pathway enrichment analysis. Results show that five of the M-tuberculosis secretory proteins within an infected host macrophage that correspond to the mycobacterial virulent strain H37Rv were extracted from the human-M- tuberculosis PPI dataset predicted by our model. Finally, a web server was created to predict PPIs between human and Mycobacterium tuberculosis which is available online at URL:http://hppredict.sanbi.ac.za. In summary, the concepts, techniques and technologies developed as part of this thesis have the potential to contribute not only to the understanding PPI analysis between human and Mycobacterium tuberculosis, but can be extended to other pathogens. Further materials related to this study are available at ftp://ftp.sanbi.ac.za/machine learning. / National Research Foundation (NRF) and SANBI

No description available.

Bacillus anthracis is a Gram positive, spore forming, non-motile, rod shaped, soil bacterium, and is endemic worldwide. Currently, the biology of B. anthracis is poorly understood. B. anthracis is one of many biological weapons used today. A -/- mutant strain of B. anthracis that lacks the pathogenic plasmids was created by serial culture at 42°C. Key DNA replication genes were identified by homology as targets. The dnaB gene, essential for B. subtilis initiation of DNA replication, was my focus. A vector system was created by polymerase chain reaction (PCR) with the pMUTIN4 integration vector and the promoter region of dnaB to study the genetics of B. anthracis. An electro-transformation system was formulated to knock-out the -/- B. anthracis dnaB gene. We have successfully incorporated the pMUTIN4 vector into the chromosomal DNA of B. anthracis. We also have formulated an electro-transformation system and vector system for use in B. anthracis.

Bacteriophages (phages) are the smallest biological entity on the planet. They provide vast amounts of valuable knowledge to biologists. Phage genomes are relatively simple compared to the organisms they infect (prokaryotes) and yet continually point to the complexity surrounding molecular- and microbiological mechanisms of life. By studying phages we can learn of the systems of gene expression, protein interaction and DNA organization. Phages are useful not only from an academic perspective, but may also have useful clinical applications. In the face of the rise of antibiotic-resistant bacterial “super pathogens”, scientists and researchers turn to phages as alternative treatments to these types of infections. Phages are capable of infecting and killing even the deadliest of bacterial pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) or Bacillus anthracis, and may prove increasingly useful in the future for combatting harmful pathogens. This thesis looks at several aspects of phage biology—from the underlying genetics contributing to phage virulence, to the clinical application of phage therapy to treat infections. First, a look at CRE-Klebsiella pneumoniae isolates and phages capable of infecting some strains may reveal a potential therapeutic approach in the future. Additionally, genomic analysis reveals interesting features that may explain aspects of phage virulence and evolutionary history. Then, a collection of genetically diverse phages is used in infection assays on pathogenic strains of Bacillus anthracis to establish the first-reported phages capable of infecting these strains. Finally, the process of preparing phage samples for therapeutic application is explored in-depth to conclude with discussion of clinical application. During the course of these projects over 25 phages were isolated, as many phage genomes were assembled and annotated, resulting in the preparation of two genome announcements and near-completion of two publishable first-author papers (chapters II and III). In addition, participation in a variety of collaborative efforts may lead to a handful of co-author papers and on various topics, including phage biology and application.

No description available.

No description available.